Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure
The human immunodeficiency virus type 1 (HIV) establishes a chronic infection that can be well controlled, but not cured, by combined antiretroviral therapy (cART). Interventions have been explored to accomplish a functional cure, meaning that a patient remains infected but HIV is undetectable in th...
Main Authors: | Hongping Jin, Dongsheng Li, Min-Hsuan Lin, Li Li, David Harrich |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/12/4/415 |
Similar Items
-
Unexpected Mutations in HIV-1 That Confer Resistance to the Tat Inhibitor Didehydro-Cortistatin A
by: Andrew P. Rice
Published: (2019-07-01) -
In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a “Block-and-Lock” Strategy for HIV-1 Treatment
by: Cari F. Kessing, et al.
Published: (2017-10-01) -
Strong In Vivo Inhibition of HIV-1 Replication by Nullbasic, a Tat Mutant
by: Hongping Jin, et al.
Published: (2019-08-01) -
Block-And-Lock Strategies to Cure HIV Infection
by: Gerlinde Vansant, et al.
Published: (2020-01-01) -
Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency
by: George B. Kyei, et al.
Published: (2018-11-01)